Indian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...

Indian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...

Indian drugmakers are stepping up to help the US combat a critical shortage of ifosfamide injection, a vital chemotherapy drug. Leading com...

Mamaearth's parent company, Honasa Consumer, is acquiring a majority stake in nutraceuticals brand Fluence Pharma for ₹135 crore. This stra...

Niti Aayog proposes a blueprint for free trade agreements to boost regulatory predictability in India's pharmaceutical sector. The think ta...

Sensex and Nifty plunged over 1% on Tuesday amid global market weakness, IT sector losses, a weaker rupee and fresh foreign fund outflows. ...

Honasa Consumer has secured a majority stake in Mumbai's hair therapy brand Fluence Pharma for Rs 135 crore. This move marks the company's ...

Honasa Consumer, parent of Mamaearth, is acquiring a 58% stake in nutraceuticals firm Fluence Pharma for Rs 135 crore, marking its entry in...

India's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...

Investor Sandip Sabharwal cautions that while the defence rally is real, many stock prices have outpaced reality. He favors Bharat Electron...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

India's defence exports are poised to surpass government targets, reaching ₹60,000-65,000 crore by 2030, according to market expert Sunil S...

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...

Indian markets saw a dip on Friday, with IT stocks leading the decline. Analysts suggest profit-taking occurred near the 24,150 mark. Despi...

India's largest drugmaker, Sun Pharma, is set to acquire Mumbai-based Innovcare Lifesciences for approximately $28.7 million in an all-cash...

Indian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...

The U.S. Federal Trade Commission (FTC) has mandated that Aurobindo Pharma must sell off four specific drug products. This action is a cond...